[Skip to Navigation]
Views 1,070
Citations 0
Editorial
April 7, 2021

Biosimilars in Dermatology

Author Affiliations
  • 1Kimberly and Eric J. Waldman Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, New York
JAMA Dermatol. Published online April 7, 2021. doi:10.1001/jamadermatol.2021.0219

Biosimilars are large complex molecules that are highly similar in structure and function to the approved brand-name molecules known as biologics. Biosimilars currently approved in the United States that could be used by dermatologists include those for rituximab, etanercept, adalimumab, and infliximab. Other approved biosimilars include those for pegfilgrastim, bevacizumab, trastuzumab, filgrastim, and epoetin alpha.

This issue of JAMA Dermatology includes 2 articles assessing biosimilars of tumor necrosis factor blockers that are used to treat a number of dermatologic and nondermatologic conditions. Loft et al1 describe a nationwide switch for patients with psoriasis in Denmark from originator adalimumab to adalimumab biosimilars and report that the 1-year drug retention for patients making that switch was the same between those switching to the biosimilar and those receiving the originator drug. The study by Westerkam et al2 compares originator infliximab with biosimilar infliximab for treatment of patients with hidradenitis suppurativa, again reporting no significant difference between the 2 treatment groups.

Limit 200 characters
Limit 25 characters
Conflicts of Interest Disclosure

Identify all potential conflicts of interest that might be relevant to your comment.

Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.

Err on the side of full disclosure.

If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.

Not all submitted comments are published. Please see our commenting policy for details.

Limit 140 characters
Limit 3600 characters or approximately 600 words
    ×